RxDoctor Payments Data

Rosario Fiore

Family · Brentwood, NYNPI 1871661280

Payments from drug & device makers

$3,090in general payments, 2019–2025

Across 158 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$777
  • Regeneron Healthcare Solutions, Inc.$285
  • Lilly USA, LLC$258
  • AbbVie$228
  • AstraZeneca$169
  • Exact Sciences$161
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$3,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,090 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide133$120,601
MounjaroTirzepatide89$93,229
TrulicityDulaglutide92$90,309
RybelsusSemaglutide23$32,517
FarxigaDapagliflozin Propanediol30$31,418
Xigduo XrDapaglifloz Propaned/Metformin31$29,462
Repatha SureclickEvolocumab32$19,688
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$17,567
JardianceEmpagliflozin17$15,724
EliquisApixaban23$15,064
XareltoRivaroxaban12$13,421
Aimovig AutoinjectorErenumab-Aooe12$8,883
VascepaIcosapent Ethyl13$8,175
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,754
Praluent PenAlirocumab15$6,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$258$183,538181 claims
Novo NordiskOzempic, Rybelsus$777$153,117156 claims
AstraZenecaFarxiga$169$31,41830 claims
GSKTrelegy Ellipta, Shingrix$17$22,23852 claims
Johnson & JohnsonXarelto$135$13,42112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Brentwood

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →